.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
Medtronic
Johnson and Johnson
Novartis
Teva
UBS
Boehringer Ingelheim
Deloitte
Daiichi Sankyo
Covington

Generated: November 18, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022012

« Back to Dashboard
NDA 022012 describes COREG CR, which is a drug marketed by Smithkline Beecham and is included in one NDA. It is available from four suppliers. There are two patents protecting this drug and three Paragraph IV challenges. Additional details are available on the COREG CR profile page.

The generic ingredient in COREG CR is carvedilol phosphate. There are thirty-six drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the carvedilol phosphate profile page.

Summary for 022012

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:2
Therapeutic Class:Cardiovascular Agents
Formulation / Manufacturing:see details

Suppliers and Packaging for NDA: 022012

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
COREG CR
carvedilol phosphate
CAPSULE, EXTENDED RELEASE;ORAL 022012 NDA GlaxoSmithKline LLC 0007-3370 0007-3370-13 30 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0007-3370-13)
COREG CR
carvedilol phosphate
CAPSULE, EXTENDED RELEASE;ORAL 022012 NDA GlaxoSmithKline LLC 0007-3371 0007-3371-13 30 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0007-3371-13)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, EXTENDED RELEASE;ORALStrength10MG
Approval Date:Oct 20, 2006TE:RLD:Yes
Patent:► SubscribePatent Expiration:Dec 27, 2023Product Flag?Substance Flag?Delist Request?Y
Patent:► SubscribePatent Expiration:Mar 11, 2026Product Flag?Substance Flag?Delist Request?Y

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, EXTENDED RELEASE;ORALStrength20MG
Approval Date:Oct 20, 2006TE:RLD:Yes
Patent:► SubscribePatent Expiration:Dec 27, 2023Product Flag?Substance Flag?Delist Request?Y

Expired Orange Book Patents for NDA: 022012

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Smithkline Beecham
COREG CR
carvedilol phosphate
CAPSULE, EXTENDED RELEASE;ORAL022012-004Oct 20, 2006► Subscribe► Subscribe
Smithkline Beecham
COREG CR
carvedilol phosphate
CAPSULE, EXTENDED RELEASE;ORAL022012-003Oct 20, 2006► Subscribe► Subscribe
Smithkline Beecham
COREG CR
carvedilol phosphate
CAPSULE, EXTENDED RELEASE;ORAL022012-004Oct 20, 2006► Subscribe► Subscribe
Smithkline Beecham
COREG CR
carvedilol phosphate
CAPSULE, EXTENDED RELEASE;ORAL022012-001Oct 20, 2006► Subscribe► Subscribe
Smithkline Beecham
COREG CR
carvedilol phosphate
CAPSULE, EXTENDED RELEASE;ORAL022012-003Oct 20, 2006► Subscribe► Subscribe
Smithkline Beecham
COREG CR
carvedilol phosphate
CAPSULE, EXTENDED RELEASE;ORAL022012-001Oct 20, 2006► Subscribe► Subscribe
Smithkline Beecham
COREG CR
carvedilol phosphate
CAPSULE, EXTENDED RELEASE;ORAL022012-004Oct 20, 2006► Subscribe► Subscribe
Smithkline Beecham
COREG CR
carvedilol phosphate
CAPSULE, EXTENDED RELEASE;ORAL022012-003Oct 20, 2006► Subscribe► Subscribe
Smithkline Beecham
COREG CR
carvedilol phosphate
CAPSULE, EXTENDED RELEASE;ORAL022012-003Oct 20, 2006► Subscribe► Subscribe
Smithkline Beecham
COREG CR
carvedilol phosphate
CAPSULE, EXTENDED RELEASE;ORAL022012-002Oct 20, 2006► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.



Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Cantor Fitzgerald
McKesson
Moodys
Teva
Chinese Patent Office
Dow
US Army
Queensland Health
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot